2022 Annual Meeting | C73 - Child Neurology: Metabolic Conditions and Genetics

Date Monday 04/04/22

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Kara S. Lewis, MD, FAAN

Topic(s) Child Neurology and Developmental Neurology

Learning Objectives Participants will review the history of neurogenetic screening, both in specific ethnic groups and pan-ethnic screening; understand the challenges of implementing genetic screening for SMA and other disorders at the state and federal level; understand current guidelines for expanded newborn, fetal and carrier genetic screening using NGS methods; obtain practical guidance for surveillance and treatment for infants with X-ALD; consider the impact of broad genomic sequence testing.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction to Metabolic Conditions and Genetics Kara S. Lewis, MD, FAAN
01:00 PM - 01:00 PM PDT	Speaker	walk in slides Kara S. Lewis, MD, FAAN
01:05 PM - 01:40 PM PDT	Speaker	Newborn Screening in the Era of Next Generation Sequencing Maura R. Ruzhnikov, MD
01:40 PM - 02:10 PM PDT	Speaker	Fetal Genetic Screening In The Era Of Next Generation Sequencing Kara S. Lewis, MD, FAAN
02:10 PM - 02:45 PM PDT	Speaker	Expanded Carrier Screening in the NGS Era Wayne Grody, MD, PhD
02:45 PM - 03:00 PM PDT	Q&A	Questions and Answers Kara S. Lewis, MD, FAAN, Vinodh Narayanan, MD, Maura R. Ruzhnikov, MD, Wayne Grody, MD, PhD

Faculty Disclosures
Kara S. Lewis, MD, FAAN	Dr. Lewis has nothing to disclose.
Vinodh Narayanan, MD	Dr. Narayanan has nothing to disclose.
Maura R. Ruzhnikov, MD	Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orchard Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Affinia Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Travere Therapeutics. Dr. Ruzhnikov has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapetuics. The institution of Dr. Ruzhnikov has received research support from Grace Science Foundation. The institution of Dr. Ruzhnikov has received research support from Ionis Pharmaceuticals. The institution of Dr. Ruzhnikov has received research support from NIH. Dr. Ruzhnikov has a non-compensated relationship as a Co-founder and Secretary with Little Zebra Fund that is relevant to AAN interests or activities.
Wayne Grody, MD, PhD	Dr. Grody has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for RavGen. The institution of Dr. Grody has received research support from ArmGenia. Dr. Grody has received publishing royalties from a publication relating to health care.